Education
About Us
Working with TipRanks
Follow Us
Tristel PLC (GB:TSTL)
LSE:TSTL
Earnings Data
Report Date
Oct 26, 2026TBA (Confirmed)
Period Ending
2026 (Q4)Consensus EPS Forecast
0.09Last Year’s EPS
0.08Same Quarter Last Year
Based on 0 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call presented a strong financial and operational performance: record revenue (14% growth), expanding adjusted EBITDA (up 17%) and robust cash generation with a debt-free balance sheet. Management highlighted meaningful U.S. commercial progress (rapidly growing procedures, product launches, distributor and OEM partnerships) and continued European expansion. Near-term headwinds include a slowdown in China/APAC, a small gross margin dip driven by in-sourcing costs and a GBP 300k intangible write-off, plus higher operating spend to fund accelerated commercial and clinical investment. Overall, the positive drivers (broad-based revenue growth, margin outperformance versus targets, strong cash and clear execution plans) materially outweigh the contained lowlights, supporting a constructive outlook.Company Guidance
Record Revenue Growth
Group revenue increased 14% year-on-year to a record GBP 25.6m in H1 FY2026 (constant-currency group growth 12.4%), driven by both UK (nearly 13% growth) and international expansion.
Strong Profitability and Margin Expansion
Adjusted profit before tax rose 11% to GBP 5.5m; adjusted EBITDA increased 17%; adjusted EPS of 9.36p. Adjusted EBITDA margin was 29%, ahead of the stated minimum commitment of 25%.
Robust Cash Position and Debt-Free Balance Sheet
Cash and deposits of GBP 13.3m, debt-free balance sheet, and strong operating cash generation of GBP 6.7m in H1, supporting progressive dividend policy and further investment.
Significant U.S. Commercial Momentum
Tristel ULT in-market sales approaching USD 1.0m with royalties/net profit contribution (reported USD/GBP mix) (Julija: $153k net profit via royalties; Anna: GBP 116k royalties), 320k procedures in H1 (3x prior year). 90 new sites onboarded in 3 months; pipeline includes 150 hot leads and 140 active engagements; management expects to exceed $2m in in-market sales by year-end.
Successful New Product Launches and Distribution Partnerships
Launched Tristel OPH with H1 revenues of $88k (ahead of initial expectations); manufacturing in U.S. by Parker Laboratories; distribution agreements with Parker, Medline, Henry Schein, Cardinal Health, Advancing Eyecare Group and Keeler USA to broaden market access; gross margins in line with group targets with scope to improve at scale.
Clinical and Regulatory Validation
Tristel ULT included in four key standards/guidelines for ultrasound probe high-level disinfection; ECRI evaluation underway; >1,200 probes confirmed compatible; OPH multicenter study underway with intent to publish peer-reviewed findings — all supporting adoption and credibility.
Geographic Recovery and European Strength
France and Italy both grew ~13% (recovery in France and tender wins in Italy); other European markets delivering double-digit growth; targeted commercial hires planned to accelerate growth in Germany, France, Italy, Middle East and Asia.
Strategic Investments in Commercial, Clinical and Digital Capabilities
Plans to add 13 commercial heads (9 salespeople, 4 clinical), recruit Chief Medical Officer and clinical portfolio leads, expand digital offerings (3T platform, web shop roll-out, internal AI agent) to build recurring revenue and sales effectiveness.
Operational Improvements and Expected Cost Savings
Wipes production in-sourced; H2 expected to see full run-rate savings of c. GBP 300k after selling prior supplier inventory; net working capital improved to 15% of annualized revenue; ROCE at 25%.
Clear Targets and On-Track Execution
Management reiterates FY2026 market expectations are on track and confirms longer-term targets (double-digit annual revenue growth FY2025–2030 and minimum adjusted EBITDA margin of 25%).
GB:TSTL Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
GB:TSTL Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Mar 02, 2026 | 400.00 p | 397.00 p | -0.75% |
Oct 13, 2025 | 349.53 p | 351.48 p | +0.56% |
Feb 24, 2025 | 333.21 p | 331.29 p | -0.58% |
Oct 21, 2024 | 372.16 p | 365.10 p | -1.90% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Tristel PLC (GB:TSTL) report earnings?
Tristel PLC (GB:TSTL) is schdueled to report earning on Oct 26, 2026, TBA (Confirmed).
What is Tristel PLC (GB:TSTL) earnings time?
Tristel PLC (GB:TSTL) earnings time is at Oct 26, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Tristel PLC stock?
The P/E ratio of Tristel is N/A.
What is GB:TSTL EPS forecast?
GB:TSTL EPS forecast for the fiscal quarter 2026 (Q4) is 0.09.